Does RADIUM RA-223 DICHLORIDE Cause Metastases to bone? 315 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 315 reports of Metastases to bone have been filed in association with RADIUM RA-223 DICHLORIDE (Xofigo). This represents 6.5% of all adverse event reports for RADIUM RA-223 DICHLORIDE.
315
Reports of Metastases to bone with RADIUM RA-223 DICHLORIDE
6.5%
of all RADIUM RA-223 DICHLORIDE reports
50
Deaths
37
Hospitalizations
How Dangerous Is Metastases to bone From RADIUM RA-223 DICHLORIDE?
Of the 315 reports, 50 (15.9%) resulted in death, 37 (11.7%) required hospitalization, and 6 (1.9%) were considered life-threatening.
Is Metastases to bone Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RADIUM RA-223 DICHLORIDE. However, 315 reports have been filed with the FAERS database.
What Other Side Effects Does RADIUM RA-223 DICHLORIDE Cause?
Prostatic specific antigen increased (449)
Hormone-refractory prostate cancer (441)
Death (376)
Anaemia (324)
General physical health deterioration (308)
Fatigue (242)
Haemoglobin decreased (236)
Prostate cancer (234)
Nausea (221)
Pain (215)
What Other Drugs Cause Metastases to bone?
LETROZOLE (1,735)
RIBOCICLIB (1,538)
FULVESTRANT (1,525)
ZOLEDRONIC ACID (1,087)
DENOSUMAB (1,053)
TAMOXIFEN (894)
LEUPROLIDE (848)
EVEROLIMUS (845)
PACLITAXEL (820)
PALBOCICLIB (793)
Which RADIUM RA-223 DICHLORIDE Alternatives Have Lower Metastases to bone Risk?
RADIUM RA-223 DICHLORIDE vs RALOXIFENE
RADIUM RA-223 DICHLORIDE vs RALTEGRAVIR
RADIUM RA-223 DICHLORIDE vs RALTITREXED
RADIUM RA-223 DICHLORIDE vs RAMELTEON
RADIUM RA-223 DICHLORIDE vs RAMIPRIL